COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects (AGSPT_PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01882296
Recruitment Status : Unknown
Verified May 2013 by Ahn-Gook Pharmaceuticals Co.,Ltd.
Recruitment status was:  Not yet recruiting
First Posted : June 20, 2013
Last Update Posted : June 20, 2013
Information provided by (Responsible Party):
Ahn-Gook Pharmaceuticals Co.,Ltd

Brief Summary:

Primary object: Evaluate Pharmacodynamic property and safety administered S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in healthy male subjects

Secondary object : Evaluate Dose-response of S-pantoprazole and pantoprazole and compare each dose-response

Condition or disease Intervention/treatment Phase
Healthy Male Subjects Drug: AGSPT_10 Drug: AGSPT_20 Drug: AGSPT_40 Drug: Pantoprazole_20 Drug: Pantoprazole_40 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects
Estimated Primary Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AGSPT_10
tablet, 10mg, QD, 7days
Drug: AGSPT_10
AGSPT 10mg for 7days administration

Experimental: AGSPT_20
tablet, 20mg, QD, 7days
Drug: AGSPT_20
AGSPT 20mg for 7days administration

Experimental: AGSPT_40
tablet, 20mg x 2, QD, 7days
Drug: AGSPT_40
AGSPT 20mg x 2tablet for 7days administration

Active Comparator: Pantoprazole_20
tablet, 20mg, QD, 7days
Drug: Pantoprazole_20
Pantoprazole 20mg for 7days administration

Active Comparator: Pantoprazole_40
tablet, 40mg, QD, 7days
Drug: Pantoprazole_40
Pantoprazole 40mg for 7days administration

Primary Outcome Measures :
  1. 24h pH [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. %Time pH>6 [ Time Frame: 24 hours ]
    (Time(hour) percent when pH >6) / 24(hours)

  2. % inhibition time gastric pH≤4 [ Time Frame: 24 hours ]
    100-(percent time pH >4)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult healthy males 20 to 45 years at screening
  • BMI : 19kg/m2 ~ 26 kg/m2
  • Blood Pressure : "140 mmHg ≥ sitting SBP ≥ 90 mmHg, 95 mmHg ≥ sitting DBP ≥ 50 mmHg"

Exclusion Criteria:

  • Have history of significant hepatic, renal gastrointestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases
  • Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer) or surgery (except for Appendectomy, hernia repair) affected the absorption of medications
  • Have history of GERD, Gastric ulcer, Duodenal ulcer and H.pylori positive
  • Hypersensitivity reactions to drugs of clinically significant hypersensitivity reactions in the history of benzimidazole (ex: pantoprazole, NSAID, antibiotic)
  • Have a history of drug abuse
  • unusual diet affected the absorption, distribution, metabolism, excretion of medications
  • Subject who treated with any investigational drugs within 90 days before the administration of investigational drug
  • Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30days
  • Previously donate whole blood within 60 days or component blood within 30 days or transfusion within 30 days
  • Subject who have taken habitually caffeine (caffeine > 5 units/day)
  • Subject who have drunken habitually (alcohol > 21 units/week, 1 unit = pure alcohol 10ml)or who are unable to quit drinking during this study or smoker
  • Subjects deemed ineligible by investigator based on other reasons
Layout table for additonal information
Responsible Party: Ahn-Gook Pharmaceuticals Co.,Ltd Identifier: NCT01882296    
Other Study ID Numbers: AGSPT_PD
First Posted: June 20, 2013    Key Record Dates
Last Update Posted: June 20, 2013
Last Verified: May 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action